麦迪森控股(08057.HK)4500万港元出售Novel Idea 55%股权
格隆汇8月27日丨麦迪森控股(08057.HK)公布,于2019年8月27日,该集团完成按代价4500万港元向一名独立第三方出售其于Novel Idea Holdings Limited(一间间接非全资附属公司)的全部55%股权。
于2019年7月31日,Novel Idea综合资产净值约为133万港元。Novel Idea主要从事软件开发及营运网上加密货币衍生工具交易平台。
董事会一直不时审阅投资组合,并认为出售事项变现投资并取得资本收益,乃符合该集团的最佳利益。该集团预期于本财政年度内确认出售事项收益约4430万港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.